A Double-blinded, Placebo-controlled, Crossover Study to Assess Efficacy of Oral Treprostinil Titrated to Highest Tolerable Dose in 20 Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon Resistant to Vasodilatory Therapy

Trial Profile

A Double-blinded, Placebo-controlled, Crossover Study to Assess Efficacy of Oral Treprostinil Titrated to Highest Tolerable Dose in 20 Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon Resistant to Vasodilatory Therapy

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Raynaud's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jul 2017 Planned number of patients changed from 30 to 20.
    • 31 Jul 2017 Planned End Date changed from 1 Jan 2018 to 1 Jul 2018.
    • 31 Jul 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top